Clinical trial · Interventional
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma
A Phase II Trial, Sequential Treatments of Dendritic Cell Vaccination Followed by Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma
NCT07726329CI-TRIAL-00119280active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dendritic cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- dendritic cell treatment
- description
- phase 2, one treatment arm
- interventionNames
- Biological: dendritic cells
Primary outcomes (2)
- measure
- Incidence of Treatment-Related Adverse Events
- timeFrame
- up to 48 months.
- description
- To evaluate the safety of the treatments by assessing the number of participants with treatment-related adverse events.
- measure
- Objective Tumor Response
- timeFrame
- From date of first treatment until the date of first documented progression, assessed up to 48 months.
- description
- To evaluate the tumor responses under the treatments as assessed by modified RECIST criteria.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * advanced HCC patients, no response to standard treatment; WBC : 3000-12000/ul; platelet: \>80000/ul; anticipated survival \> 3 months, measurable tumors. Exclusion Criteria: * HIV; BCLC stage; acute infection; sepsis; other advanced malignancy; acute liver failure;
References
Publications (0)
Data not yet available
No reference posted for this study.